Strategic Acquisition Drugscan was acquired by ACM Global Laboratories in late 2017, indicating a consolidation trend in toxicology and infectious disease testing services. Target opportunities may exist by aligning with ACM Global’s expanded portfolio and cross-selling complementary testing services to their existing client base.

Diversified Testing With capabilities spanning prescription drug and addiction monitoring, workplace drug testing, and infectious disease testing including real-time PCR for COVID-19, Drugscan presents multiple entry points for new contracts across corporate wellness programs, occupational health partnerships, and public health surveillance collaborations.

Regional Footprint Operating across 48 states from a central Horsham, PA base, Drugscan has broad geographic reach which can be leveraged to propose scalable nationwide testing programs, multi-site workplace solutions, and streamlined onboarding for large employers with distributed workforces.

Compliance & Quality Certified laboratories (CAP and SAMSHA) signal strong quality and regulatory compliance, enabling sales conversations focused on risk management, audit readiness, and enterprise-level testing programs for regulated industries seeking dependable, standards-aligned partners.

Small to Mid‑Market Scale With 51-200 employees and revenue in the $50M–$100M range, Drugscan sits between smaller boutique labs and larger national players, presenting an opportunity to win mid-market deals through flexible service models, program management capabilities, and competitively tailored pricing for mid-sized organizations.